Objectives: Patients whose tumors harbor ROS1 translocation may benefit from targeted therapy. Detection of ROS1 rearrangement can be done by three methods: immunohistochemistry, fluorescence in situ hybridization, and molecular assays. Immunohistochemistry would be a cost-effective means to screen for ROS1 translocation, which is uncommon.
Results: Fifty-seven cases, 10 lung carcinomas with ROS1 rearrangement and 47 cases without ROS1 rearrangement (25 lung carcinomas, 13 gastrointestinal carcinomas, three brain tumors, and six miscellaneous tumors), were included. ROS1 immunostain exhibited 100% sensitivity and 85% specificity, with staining seen in 10 (100%) of 10 cases with ROS1 rearrangement and in seven (15%) of 47 lung cases without ROS1 rearrangement. Weak or 1þ staining of reactive pneumocytes was seen in eight (14%) of 57 cases, and strong staining of osteoclast giant cells was seen in one case.
Conclusions: Since ROS1 rearrangement is an infrequent event, immunohistochemistry is a cost-effective screening method. Confirmation of all positive and equivocal/weak staining with molecular assays would exclude the falsepositive cases.
Rearrangement of ROS1, a receptor tyrosine kinase oncogene, has been reported in a number of malignancies, including non-small cell lung carcinoma, gastric adenocarcinoma, colonic adenocarcinoma, intrahepatic cholangiocarcinoma, ovarian carcinoma, angiosarcoma, inflammatory myofibroblastic tumors, and glioblastoma multiforme. [1] [2] [3] [4] [5] [6] [7] [8] The fusion gene partners include CCDC6, CD74, EZR, FIG1 (or GOPC), KDELR2, LRIG3, SDC4, SLC34A2, and TPM3. 9, 10 All involve fusion of the 3 0 region of the kinase domain of ROS1 to the 5 0 region of the partner gene. 9 These rearrangements result in activation of the kinase domain of ROS1 with subsequent cellular proliferation and oncogenic transformation. 10 Although Rimkunas et al 11 reported two cases with concurrent EGFR mutations and ROS1 rearrangement, tumors with ROS1 fusion do not typically harbor other oncogenic mutations such as EGFR mutation and ALK rearrangement. 1, 12 Crizotinib, a multitargeted kinase Upon completion of this activity you will be able to:
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inhibitor, has recently been approved by the US Food and Drug Administration for treatment of ALK-rearranged nonsmall cell lung carcinoma. Recently, crizotinib has been shown to have therapeutic effect in the treatment of ROS1-rearranged tumors. 13, 14 Thus, patients whose tumors harbor ROS1 translocation may benefit from targeted therapy. Detection of ROS1 rearrangement can be done by different methods, including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and reverse transcription-polymerase chain reaction (RT-PCR). ROS1 rearrangements involve a growing number of fusion partners; thus, multiple primer sets are required for RT-PCR screening, and novel rearrangements will be missed. FISH tests can only detect specific translocation targeted by designated probes and therefore also miss novel rearrangements. In addition, FISH would require special microscope and technical expertise and thus is not available in many laboratories. IHC is less laborious, cost saving, and more widely available than FISH and RT-PCR assays. It would be a costeffective means to screen for ROS1 translocation, which is uncommon, with a reported prevalence of only 1%, 1.64%, and 1.7% in 167, 183, and 1,073 non-small cell lung carcinoma carcinomas, respectively. 1, 12, 15 ROS1 is primarily expressed during embryonic development, and ROS1 proteins are not commonly detected in normal lung and normal tissues. ROS1 rearrangement has been reported to correlate with ROS1 protein levels. 9, 11, 12, [15] [16] [17] Although these series included a large number of cases, only one to 17 ROS1 rearranged cases have been included, with the remaining cases lacking ROS1 rearrangement. 9, 11, 12, 15, 16 We aim to assess the sensitivity and specificity of ROS1 immunostain in the detection of ROS1 rearrangement in a series of cases at our institutions.
Materials and Methods
The study was approved by Massachusetts General Hospital institutional board review (protocol 2008P002165). Archival, formalin-fixed, and paraffinembedded materials of tumors submitted for ROS1 rearrangement either by FISH or next-generation sequencing (NGS) assays at the Molecular Diagnostic Laboratory, Massachusetts General Hospital, Boston, between 2010 and 2015, were retrieved from the pathology files. Whenever possible, the same tumor block on which molecular testing performed was selected for immunohistochemical studies.
FISH
FISH was performed on 5-lm sections from formalinfixed, paraffin-embedded tumor tissue. A break-apart ROS1 FISH assay, using green and red fluorescently labeled bacterial artificial chromosome clones corresponding to the 5 0 (RP11-835I21) and 3 0 (RP11-1036C2) sequences flanking the ROS1 gene, was used to detect ROS1 gene rearrangements, as previously described.
1 NGS ROS1 fusions were detected using a previously described targeted gene rearrangement assay. 18 Briefly, total nucleic acid (TNA) containing total RNA and genomic DNA was extracted from formalin-fixed, paraffinembedded tissue using the Agencourt Forma Pure Kit (Beckman Coulter, Indianapolis, IN). Then, 50 ng TNA was used for rearrangement analysis, which was based on anchored multiplex PCR with universal adapters and genespecific primers, followed by NGS using MiSeq (Illumina, San Diego, CA). 18 The targeted genes (exons) covered by the assay include ADCK4 (1-2, 4-6, 9-10, 12-15), 
(1, 31-37, 43), and TMPRSS2 (1-5).
IHC
Immunohistochemical studies were performed on 5-lm-thick sections of formalin-fixed, paraffin-embedded tissue in a Bond 3 automated immunostainer (Leica Microsystems, Bannockburn, IL) and primary antibodies against ROS1 (clone: D4D6, 1:200; Cell Signaling Technology, Danvers, MA). Appropriate positive and negative controls were included. A lung adenocarcinoma with a known ROS1 translocation and a colonic adenocarcinoma without known ROS1 translocation were used as positive and negative controls, respectively. Positive staining was characterized by diffuse cytoplasmic with some membranous staining of the tumor cells. The intensity of staining was graded as 0, no staining; 1þ, weak staining; 2þ, moderate staining in 1% to 50%; and 3þ, strong cytoplasmic staining in more than 50% of tumor cells. 12 The slides were reviewed independently by two authors (Y.S. and M.P.H.) and then together at a multiheaded microscope to achieve consensus.
Results
Fifty-seven cases were included in the study. Ten lung carcinomas with ROS1 rearrangement (four by FISH and six by NGS assays) and available archival materials were identified Image 1 . Of these 10 cases with ROS1 rearrangement, one tumor also harbored TP53, SMAD4, and APC mutations and two tumors with TP53 mutation. The different translocations are outlined in Table 1 .
Forty-seven cases of various tumor types and without ROS1 rearrangement by NGS were included. They comprised 25 lung carcinomas (19 primary, six metastatic), 13 gastrointestinal carcinomas (eight primary, three metastatic), three brain tumors (one glioblastoma multiforme, one glioneuronal tumor, one anaplastic meningioma), and six miscellaneous tumors (one synovial sarcoma, one Warthin tumor, one papillary thyroid carcinoma, one urothelial transitional cell carcinoma, one thymic neuroendocrine carcinoma, one inflammatory pseudotumor). Mutation involving a single gene, including BRAF, EGFR, FBXW7, KRAS, LIK3R1, or TP53, was noted in 15 cases. Mutations involving multiple genes (from two to five), including APC, BRAF, CDH1, CDKN2A, DDR2, EGFR, EGFR2, FBXW7, FGFR1, GNAS, KRAS, MAP2K1, NOTCH1, PIK3CA, PTEN, RET, SMAD4, STK11, and TP53, were noted in 22 cases. The remaining cases were negative.
The immunohistochemical results are summarized in and Figure 1 . Weak or 1þ staining of reactive pneumocytes was seen in eight (14%) of 57 cases, and strong B A Image 1 A, The nucleus has two normal signals (with green and orange fluorescence probes juxtaposed) indicating that the ROS1 gene is intact. B, The nucleus has one normal signal and one split signal (the green and orange probes are split, as noted by the arrows) indicating ROS1 rearrangement. 
Discussion
As seen in ours and previously reported in other series, using either FISH or RT-PCR as the gold standard, the sensitivity of ROS1 immunostain is better than its specificity (Table 2) . 2, 9, 12, [15] [16] [17] [19] [20] [21] With the exception of the 33% sensitivity reported by Rogers et al, 16 most studies reported sensitivity that ranged from 94% to 100%. 2, 9, 12, [15] [16] [17] [19] [20] [21] On the other hand, specificity of most studies dropped to within the 90% to 98% range. Cao et al 15 evaluated the three methods in the detection of ROS1 rearrangement in 183 lung adenocarcinomas and found IHC to have 100% sensitivity and 97.6% specificity; however, the authors included only three cases harboring ROS1 rearrangement. Sholl et al 12 compared IHC with FISH and reported 100% sensitivity and 92% specificity in 53 lung adenocarcinomas. Using the same criterion reported by Sholl et al, 12 Yoshida et al, 9 and Cao et al, 15 with 75% of tumor or greater staining and with 2þ or greater staining intensity being positive, we observed 100% sensitivity. 3þ ROS1 protein expression correlated with 98% specificity in the series by Sholl et al 12 and 100% in ours. Faint 1þ staining in tumor cells was not uncommon in the series by Sholl et al. 12 Although additional studies with a larger number of cases from various tumor types are warranted, it appears that lung carcinomas are more likely to exhibit false positivity than other tumor types. A number of other reasons could account for low specificity of ROS1 immunostain. Preanalytic variables such as tissue processing, fixation time, and block storage condition may affect the antigenicity of the tissue. Lack of messenger RNA preservation in the extracted tissue, a low level of the expressed ROS1 fusion transcript, and an alternative mechanism of ROS1 overexpression might account for cases with positive IHC yet negative FISH/RT-PCR, a falsely negative molecular result. FISH might not detect ROS1-EZR and other fusions since these two genes are located on the same chromosome.
Most of our cases without ROS1 fusion harbor a number of mutations, yet ROS1 immunostains are negative for these cases, supportive of the stain's specificity for this particular fusion. As previously reported, we also observed ROS1 staining in nonneoplastic tissue, including osteoclast giant cells, reactive pneumocyte hyperplasia, and bronchiolar metaplasia. 9, 12, 20 Some authors have recommended not to score ROS1 staining in areas in which pneumocyte hyperplasia cannot be distinguished from adenocarcinoma in situ. 9, 12 The variability in sensitivity and specificity of different studies could be due in part to the different scoring criteria. Some authors used an H-score system, with "150" as a cutoff by some and "100" as a cutoff by others. 9, 17, 20 Similar to Rogers et al, 16 Shan et al, 21 and Cao et al, 15 we scored any staining as positive expression. While using 2þ or more as a cutoff, Sholl et al 12 confirmatory molecular testing on all positive cases (1-3þ) is necessary. Although most cases showed granular cytoplasmic staining, distinctive ROS1 staining patterns associated with fusion type have been observed in some tumors. Two of our cases with EZR-ROS1 translocation exhibited strong membranous staining in areas. Similarly, lung carcinomas with EZR-ROS1 fusion have been reported to exhibit strong membranous staining. 9, 17 A globular paranuclear pattern has been reported for some of the lung carcinomas with CD74-ROS1 fusion 9, 17 ; however, we did not observe this staining pattern in our three cases with CD74-ROS1 fusion. Although not described in the series by Cao et al, 15 one lung carcinoma with CD74-ROS1 fusion appears to have a globular staining pattern per published photomicrograph. SLC-ROS1 tumors do not appear to have distinctive staining pattern. 
